Blockstream’s Bitcoin Mining Security Token Projected to Outperform Direct Bitcoin Investments
Blockstream Mining Note 2 (BMN2) Series 3 is Open with a 4-Year Fixed Cost of $31,000 PH/s.The Most Cost-Effective, Effortless Way for Eligible Investors to Actively Participate in Proof-of-Work Rewards.
Blockstream, the global leader in Bitcoin infrastructure technology, has launched series 3 of its highly anticipated Blockstream Mining Note 2 (BMN2), responding once again to heightened investor interest in Bitcoin mining opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905372943/en/
(Graphic: Business Wire)
BMN2, an EU-compliant hash rate-backed security token, provides direct exposure to Bitcoin hash rate operated by Blockstream’s state-of-the-art, enterprise-grade mining facilities across North America. BMN2 is designed to replicate the first iteration of the Blockstream Mining Note (BMN1), which launched in 2021 and matured in July this year, delivering a 32% bitcoin return over its 3-year term. Arnab Naskar, Co-founder and Co-CEO of STOKR, a digital asset investment platform, declares it “the highest payout in real world asset (RWA) security token history.”
The Bitcoin industry has matured greatly since the launch of BMN1 in 2021. Bitcoin mining-adjacent investment products, such as hash rate contracts and hosted mining services, have become available to investors and businesses. However, these products and services lack investment conveniences — secondary market liquidity, long-term fixed rates, instant exposure, and market timing protection — freedoms that BMN2 provides.
BMN2—the primary offering of which went live on July 18, 2024 raising just under $7M—follows a similar economic model to BMN1, offering a highly competitive hash price for investors and an investment opportunity that can outpace bitcoin purchases on the spot market. Further, BMN2 includes hash rate safeguards that exceed that of its predecessor, including a reserve of 50% of the stated hash rate (1PH/s per day) to protect against potential miner failures, reduced efficiency, and other non-force majeure issues.
Available to qualified, non-US investors via Luxembourg-based virtual assets service provider, STOKR, BMN2 is offered at a set, discounted hash price of $21.23 for 48 months. Bitcoin hash price refers to the short-term profitability of bitcoin mining and measures the revenue that Bitcoin miners can earn. The BMN2 is prominently priced well below the current spot market hash price to incentivize bitcoin holders, investors, and businesses to directly partake in maintaining the Bitcoin network. Each BMN2 security token entitles holders to the bitcoin produced by 1 PH/s (petahash per second) of Blockstream’s mining hash rate, ensuring a consistent stream of bitcoin rewards directly linked to mining performance. BMN2 provides a well-timed onramp for investors to strategically take part in the market before the next bitcoin halving.
Bitcoin mining operations for BMN2 commenced this week at an equivalent hosting rate less than $.045 kWh (kilowatt-hour), which is substantially lower than the industry average of $.065 for enterprises, and $.075 commonly available for retail customers. The strength, reliability, and performance of Blockstream’s advanced mining fleet allows for the extension of favorable terms to the greater Bitcoin community to contribute to the network’s decentralization. Additionally, over 80% of BMN2 power is derived from carbon neutral sources—wind, solar, and nuclear—making it a conscientious investment opportunity that aligns investor interests, community collaboration, and offers an attractive entry point relative to the historical hash price market.
“Operational excellence and integrity are at the core of our mining business,” said Chris Cook, CIO of Blockstream. “We know first-hand the complexities involved in mining Bitcoin—hardware challenges, energy curtailment, and price fluctuation, to name a few. We created the BMN product to deliver a consistent hash rate with the goal of maintaining a strong and steady investment outcome.”
Blockstream’s leadership in Bitcoin mining is well-established. It traces its roots back to CEO and Co-founder Dr. Adam Back’s invention of the HashCash algorithm behind the proof-of-work protocol, a fundamental component of Bitcoin’s security architecture. Dr. Back’s pioneering work laid the groundwork for Bitcoin, and his ongoing contributions with the BMN and BASIC note, another Blockstream mining offering, to continue to shape the future of the entire real world asset industry.
For access to the BMN2 security token offering and regular updates, eligible investors can register at https://stokr.io/featured-assets/blockstream-mining2.
About Blockstream Mining
Founded in 2014, Blockstream is the global leader in Bitcoin and blockchain infrastructure. Blockstream Mining offers turnkey Bitcoin mining services and solutions designed to provide institutions full transparency and control over their mining operations. By providing secure state-of-the art facilities for a reliable miner colocation, coupled with exceptional technical talent infrastructure, Blockstream Mining purpose-built data centers meet the strict physical and network security requirements of global institutional and enterprise customers. Keeping mining carbon emissions to a minimum, current mining sites are located in the US and Canada, using a majority of non-fossil power sources.
About STOKR
STOKR is at the forefront of transforming financial assets for the digital era. As a leading digital investment platform, STOKR helps asset managers, fund managers, and issuers to tokenize and manage a diverse range of financial assets. STOKR’s platform simplifies the entry into the world of digital securities with a comprehensive suite of services that includes dedicated investment structures, state-of-the-art technology infrastructure, and full-scale support in payments and compliance.
With STOKR, clients can effortlessly issue digital securities and foster strong investor relationships, benefiting from enhanced liquidity thanks to the integration with secondary markets. STOKR’s approach removes the technical complexities typically associated with digital securities, offering a seamless investment experience. Leveraging over six years of innovation and expertise in the digital securities market, STOKR provides a sophisticated and secure environment for capital raising.
Registered as a Virtual Assets Service Provider (VASP) with the CSSF in Luxembourg, STOKR is committed to the highest standards of regulatory compliance, ensuring a reliable and trustworthy platform for all stakeholders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905372943/en/
Contacts
Sarah L. Macedonio
Sarah L. Macedonio
sarah@mining.blockstream.com
(860) 573-9580
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom